magnifying glass
logo for Sarepta Therapeutics

Sarepta Therapeutics

Get Full Access

Description

Established in 1980, Sarepta Therapeutics conducts research on and manufactures pharmaceuticals used to treat genetic diseases. This company is headquartered in... Read More

Headquarters

Headquarters:

215 First Street, Cambridge, Massachusetts, 02142, United States
Phone

Phone:

(617) 274-4000
Employees

Employees:

743
Revenue

Revenue:

$380 Million
Stock Symbol

Stock Symbol:

SRPT
Sarepta Therapeutics's Social Media
SIC Code 28,283
NAICS Code 541,32541
Ticker NASDAQ: SRPT
Popular Searches:

Sarepta Therapeutics Inc

sarepta therapeutics , inc.

Sarepta Therapeutics

sarepta therapeutics, inc.

Sarepta Therapeutics Inc.

Top Competitors of Sarepta Therapeutics

Employess
817
revenue
$599 Million

1

Employess
252
revenue
<$5 Million

2

Employess
1,323
revenue
$219 Million

3

Employess
700
revenue
$51 Million

4

Employess
269
revenue
$251 Million

5

Employess
350
revenue
$42 Million

6

Sarepta Therapeutics's Org Chart

Leslie Hudson
Leslie Hudson

President & Chief Executive Officer

PhonePhoneEmailEmail
Princess Hernandez-Wilson
Princess Hernandez-Wilso...

Director, Analytical and Quality Co...

PhonePhoneEmailEmail
Ian Estepan
Ian Estepan

Executive VP & Chief Financial Offi...

PhonePhoneEmailEmail

PhonePhoneEmailEmail

PhonePhoneEmailEmail
Illustration of an envelope

Sarepta Therapeutics Company Metrics

Company Insights
Employee Growth Rate
Funding
Funding DateRoundAmountInvestors

Dec 13, 2019

Debt

$250M

Pharmakon Advisors, LP

Nov 25, 2019

Unspecified

$30M

Undisclosed

Mar 05, 2019

Stock Issuance/Offering

$375M

Morgan Stanley & Co.

See More

$2B

Total Funding Amount

$250M

Most Recent Funding Amount

17

Number of Funding Rounds

Revenue
QuarterRevenue

'20 - Q3

301034000

'20 - Q4

301034000

'21 - Q1

380833000

'21 - Q2

380833000

Acquisitions & Subsidiaries

Jan 15, 2018

Myonexus Therapeutics

Exegenics

Ercole Biotech

See More Acquisitions & Subsidiaries

Sarepta Therapeutics's Tech Stack

Acquia Cloud

By

Acquia

Microsoft Project

By

Microsoft

ADP

By

ADP

Arcserve Backup

By

Arcserve

Formstack

By

Formstack

Drupal

By

Drupal
See more technologies

Sarepta Therapeutics News & Media

Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy

CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced topline results from Part 2 of Study SRP-9001-102 (Study 102), an ongoing, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety, efficacy and tolerability of a single dose of SRP-9001 (delandistrogene moxeparvovec) in 41 patients with Duchenne muscular dystrophy, 21 of whom were in the placebo cross

Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 10, 2022 at 10:30 a.m. E.T. / 7:30 a.m. P.T. Following the presentation there will be a Q&A session starting at 10:50 a.m. E.T. / 7:50 a.m. P.T.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 25 individuals hired by Sarepta in December 2021. The equity awards were approved in accordance with Nasdaq Listin
Subscribe to "Sarepta Therapeutics" News

Frequently Asked Questions regarding Sarepta Therapeutics

Where are Sarepta Therapeutics’s headquarters?

Sarepta Therapeutics’s headquarters are in 215 First Street, Cambridge, Massachusetts, 02142, United States

What is Sarepta Therapeutics’s phone number?

Sarepta Therapeutics’s phone number is (617) 274-4000

What is Sarepta Therapeutics’s stock symbol?

Sarepta Therapeutics’s stock symbol is SRPT

What is Sarepta Therapeutics’s official website?

Sarepta Therapeutics’s official website is //www.sarepta.com

What is Sarepta Therapeutics’s Revenue?

Sarepta Therapeutics’s revenue is $380 Million

What is Sarepta Therapeutics’s SIC code?

Sarepta Therapeutics’s SIC: 28,283

What is Sarepta Therapeutics’s NAICS code?

Sarepta Therapeutics’s NAICS: 541,32541

How many employees are working in Sarepta Therapeutics?

Sarepta Therapeutics has 743 employees

What is Sarepta Therapeutics’s industry?

Sarepta Therapeutics is in the industry of: Drug Manufacturing & Research, Pharmaceuticals, Healthcare

Who are Sarepta Therapeutics’s main competitors?

Sarepta Therapeutics's main competitors are: Ionis Pharmaceuticals, Orchard Therapeutics, Alnylam Pharmaceuticals, Ultragenyx Pharmaceutical

What companies has Sarepta Therapeutics acquired?

Sarepta Therapeutics has acquired the companies: Myonexus Therapeutics, Exegenics, Ercole Biotech

What is Sarepta Therapeutics's tech stack?

The technologies that are used by Sarepta Therapeutics are: Acquia Cloud, Microsoft Project, ADP, Arcserve Backup

Who is Sarepta Therapeutics's CEO?

Sarepta Therapeutics's CEO is Leslie Hudson

Who is Sarepta Therapeutics's CFO?

Sarepta Therapeutics's CFO is Ian Estepan

See more information about Sarepta Therapeutics

Browse ZoomInfo’s Directories